SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001851734-23-000029
Filing Date
2023-02-02
Accepted
2023-02-02 09:10:25
Documents
14
Period of Report
2023-02-02
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vtgn20230201_8k.htm   iXBRL 8-K 27313
2 EXHIBIT 99.1 ex_470856.htm EX-99.1 9676
  Complete submission text file 0001851734-23-000029.txt   174499

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vtgn-20230202.xsd EX-101.SCH 3600
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vtgn-20230202_def.xml EX-101.DEF 11531
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtgn-20230202_lab.xml EX-101.LAB 15413
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtgn-20230202_pre.xml EX-101.PRE 11687
8 EXTRACTED XBRL INSTANCE DOCUMENT vtgn20230201_8k_htm.xml XML 2593
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
VistaGen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 23578970
SIC: 2834 Pharmaceutical Preparations